Cargando…
Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury
The kidney is not typically the main target of severe acute respiratory syndrome coronavirus 2, but surprisingly, acute kidney injury (AKI) may occur in 4–23% of cases, whereas the dialysis management of AKI from coronavirus 2019 has not gained much attention. The severity of the pandemic has result...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337686/ https://www.ncbi.nlm.nih.gov/pubmed/32695319 http://dx.doi.org/10.1093/ckj/sfaa102 |
_version_ | 1783554557575430144 |
---|---|
author | Ponce, Daniela Balbi, André L Durand, Jonathan B Moretta, Gustavo Divino-Filho, José C |
author_facet | Ponce, Daniela Balbi, André L Durand, Jonathan B Moretta, Gustavo Divino-Filho, José C |
author_sort | Ponce, Daniela |
collection | PubMed |
description | The kidney is not typically the main target of severe acute respiratory syndrome coronavirus 2, but surprisingly, acute kidney injury (AKI) may occur in 4–23% of cases, whereas the dialysis management of AKI from coronavirus 2019 has not gained much attention. The severity of the pandemic has resulted in significant shortages in medical supplies, including respirators, ventilators and personal protective equipment. Peritoneal dialysis (PD) remains available and has been used in clinical practice for AKI for >70 years; however, it has been used on only a limited basis and therefore experience and knowledge of its use has gradually vanished, leaving a considerable gap. The turning point came in 2007, with a series of sequential publications providing solid evidence that PD is a viable option. As there was an availability constraint and a capacity limit of equipment/supplies in many countries, hemodialysis and convective therapies became alternatives. However, even these therapies are not available in many countries and their capacity is being pushed to the limit in many cities. Evidence-based PD experience lends support for the use of PD now. |
format | Online Article Text |
id | pubmed-7337686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-73376862020-07-08 Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury Ponce, Daniela Balbi, André L Durand, Jonathan B Moretta, Gustavo Divino-Filho, José C Clin Kidney J Editorial Comments The kidney is not typically the main target of severe acute respiratory syndrome coronavirus 2, but surprisingly, acute kidney injury (AKI) may occur in 4–23% of cases, whereas the dialysis management of AKI from coronavirus 2019 has not gained much attention. The severity of the pandemic has resulted in significant shortages in medical supplies, including respirators, ventilators and personal protective equipment. Peritoneal dialysis (PD) remains available and has been used in clinical practice for AKI for >70 years; however, it has been used on only a limited basis and therefore experience and knowledge of its use has gradually vanished, leaving a considerable gap. The turning point came in 2007, with a series of sequential publications providing solid evidence that PD is a viable option. As there was an availability constraint and a capacity limit of equipment/supplies in many countries, hemodialysis and convective therapies became alternatives. However, even these therapies are not available in many countries and their capacity is being pushed to the limit in many cities. Evidence-based PD experience lends support for the use of PD now. Oxford University Press 2020-06-30 /pmc/articles/PMC7337686/ /pubmed/32695319 http://dx.doi.org/10.1093/ckj/sfaa102 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Editorial Comments Ponce, Daniela Balbi, André L Durand, Jonathan B Moretta, Gustavo Divino-Filho, José C Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury |
title | Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury |
title_full | Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury |
title_fullStr | Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury |
title_full_unstemmed | Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury |
title_short | Acute peritoneal dialysis in the treatment of COVID-19-related acute kidney injury |
title_sort | acute peritoneal dialysis in the treatment of covid-19-related acute kidney injury |
topic | Editorial Comments |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337686/ https://www.ncbi.nlm.nih.gov/pubmed/32695319 http://dx.doi.org/10.1093/ckj/sfaa102 |
work_keys_str_mv | AT poncedaniela acuteperitonealdialysisinthetreatmentofcovid19relatedacutekidneyinjury AT balbiandrel acuteperitonealdialysisinthetreatmentofcovid19relatedacutekidneyinjury AT durandjonathanb acuteperitonealdialysisinthetreatmentofcovid19relatedacutekidneyinjury AT morettagustavo acuteperitonealdialysisinthetreatmentofcovid19relatedacutekidneyinjury AT divinofilhojosec acuteperitonealdialysisinthetreatmentofcovid19relatedacutekidneyinjury |